Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis

Patricia Juárez, Pierrick G.J. Fournier, Khalid Mohammad, Ryan C. McKenna, Holly W. Davis, Xiang H. Peng, Maria Niewolna, Alain Mauviel, John Chirgwin, Theresa Guise

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloidderivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-β-regulated metastatic genes. Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-β-receptor II protein. Proline supplementation but not Smad7-knockdown reversed halofuginone-inhibition of TGF-β-signaling. Halofuginone also decreased BMP-signaling. Treatment of MDA-MB-231 and PC3 cells with halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation and mRNA of the BMP-regulated gene Id-1. Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. Furthermore, halofuginone decreased tumor-take and growth of orthotopictumors. Mice with breast or prostate bone metastases treated with halofuginone had significantly less osteolysis than control mice. Combined treatment with halofuginone and zoledronic-acid significantly reduced osteolytic area more than either treatment alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer.

Original languageEnglish (US)
Pages (from-to)86447-86462
Number of pages16
JournalOncotarget
Volume8
Issue number49
DOIs
StatePublished - Oct 17 2017

Fingerprint

zoledronic acid
Bone Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
halofuginone
Prostatic Neoplasms
Phosphorylation
Smad Proteins

Keywords

  • BMP
  • Bone metastases
  • Halofuginone
  • TGF-β
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology

Cite this

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. / Juárez, Patricia; Fournier, Pierrick G.J.; Mohammad, Khalid; McKenna, Ryan C.; Davis, Holly W.; Peng, Xiang H.; Niewolna, Maria; Mauviel, Alain; Chirgwin, John; Guise, Theresa.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 86447-86462.

Research output: Contribution to journalArticle

Juárez, Patricia ; Fournier, Pierrick G.J. ; Mohammad, Khalid ; McKenna, Ryan C. ; Davis, Holly W. ; Peng, Xiang H. ; Niewolna, Maria ; Mauviel, Alain ; Chirgwin, John ; Guise, Theresa. / Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. In: Oncotarget. 2017 ; Vol. 8, No. 49. pp. 86447-86462.
@article{ff1f46f238b24f9ab02e9e1261486300,
title = "Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis",
abstract = "More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloidderivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-β-regulated metastatic genes. Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-β-receptor II protein. Proline supplementation but not Smad7-knockdown reversed halofuginone-inhibition of TGF-β-signaling. Halofuginone also decreased BMP-signaling. Treatment of MDA-MB-231 and PC3 cells with halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation and mRNA of the BMP-regulated gene Id-1. Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. Furthermore, halofuginone decreased tumor-take and growth of orthotopictumors. Mice with breast or prostate bone metastases treated with halofuginone had significantly less osteolysis than control mice. Combined treatment with halofuginone and zoledronic-acid significantly reduced osteolytic area more than either treatment alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer.",
keywords = "BMP, Bone metastases, Halofuginone, TGF-β, Zoledronic acid",
author = "Patricia Ju{\'a}rez and Fournier, {Pierrick G.J.} and Khalid Mohammad and McKenna, {Ryan C.} and Davis, {Holly W.} and Peng, {Xiang H.} and Maria Niewolna and Alain Mauviel and John Chirgwin and Theresa Guise",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.21200",
language = "English (US)",
volume = "8",
pages = "86447--86462",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

TY - JOUR

T1 - Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis

AU - Juárez, Patricia

AU - Fournier, Pierrick G.J.

AU - Mohammad, Khalid

AU - McKenna, Ryan C.

AU - Davis, Holly W.

AU - Peng, Xiang H.

AU - Niewolna, Maria

AU - Mauviel, Alain

AU - Chirgwin, John

AU - Guise, Theresa

PY - 2017/10/17

Y1 - 2017/10/17

N2 - More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloidderivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-β-regulated metastatic genes. Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-β-receptor II protein. Proline supplementation but not Smad7-knockdown reversed halofuginone-inhibition of TGF-β-signaling. Halofuginone also decreased BMP-signaling. Treatment of MDA-MB-231 and PC3 cells with halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation and mRNA of the BMP-regulated gene Id-1. Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. Furthermore, halofuginone decreased tumor-take and growth of orthotopictumors. Mice with breast or prostate bone metastases treated with halofuginone had significantly less osteolysis than control mice. Combined treatment with halofuginone and zoledronic-acid significantly reduced osteolytic area more than either treatment alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer.

AB - More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloidderivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-β-regulated metastatic genes. Halofuginone increased inhibitory Smad7-mRNA and reduced TGF-β-receptor II protein. Proline supplementation but not Smad7-knockdown reversed halofuginone-inhibition of TGF-β-signaling. Halofuginone also decreased BMP-signaling. Treatment of MDA-MB-231 and PC3 cells with halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation and mRNA of the BMP-regulated gene Id-1. Halofuginone decreased immunostaining of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo. Furthermore, halofuginone decreased tumor-take and growth of orthotopictumors. Mice with breast or prostate bone metastases treated with halofuginone had significantly less osteolysis than control mice. Combined treatment with halofuginone and zoledronic-acid significantly reduced osteolytic area more than either treatment alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer.

KW - BMP

KW - Bone metastases

KW - Halofuginone

KW - TGF-β

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=85031489892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031489892&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21200

DO - 10.18632/oncotarget.21200

M3 - Article

VL - 8

SP - 86447

EP - 86462

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -